Oncolytics Biotech

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Employees: 26

Market Cap: $74.3M

Website

Introduction: Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Ma...

Clinical Trials

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Phase 2

Active, not recruiting

Conditions: Breast Cancer Metastatic

Interventions: Drug: Paclitaxel
Biological: Pelareorep
Drug: Avelumab

First Posted Date: 2020-01-02

Last Posted Date: 2023-11-30

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 48

Registration Number: NCT04215146

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States

and more 15 locations

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

Early Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Biological: Pelareorep
Drug: Trastuzumab
Drug: Letrozole
Drug: Atezolizumab

First Posted Date: 2019-09-25

Last Posted Date: 2022-08-15

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 26

Registration Number: NCT04102618

Locations: 🇪🇸
Hospital Clínico Universitario de Valencia, Valencia, Spain
🇪🇸
Hospital La Paz, Madrid, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain

and more 11 locations

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Phase 1

Withdrawn

Conditions: Muscle-invasive Transitional Cell Carcinoma of the Bladder

First Posted Date: 2016-03-31

Last Posted Date: 2017-03-07

Lead Sponsor: Oncolytics Biotech

Registration Number: NCT02723838

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Phase 1

Completed

Conditions: Pancreatic Adenocarcinoma

First Posted Date: 2015-12-03

Last Posted Date: 2018-09-13

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 11

Registration Number: NCT02620423

Locations: 🇺🇸
Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas, United States

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: KRAS Mutant Metastatic Colorectal Cancer

First Posted Date: 2011-01-11

Last Posted Date: 2018-12-19

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 36

Registration Number: NCT01274624

Locations: 🇺🇸
Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸
New York Presbyterian Hospital/ Weill Cornell Medical College, New York, New York, United States

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Phase 3

Completed

Conditions: Carcinoma, Squamous Cell of the Head and Neck

Interventions: Biological: REOLYSIN
Drug: Carboplatin
Drug: Placebo
Drug: Paclitaxel

First Posted Date: 2010-07-21

Last Posted Date: 2014-11-05

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 167

Registration Number: NCT01166542

Locations: 🇺🇸
Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸
Wilshire Oncology Medical Group, Corona, California, United States
🇺🇸
Pasco Hernando Oncology Associates, PA, New Port Richey, Florida, United States

and more 74 locations

A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma

Phase 2

Completed

Conditions: Metastatic Pancreatic Adenocarcinoma

First Posted Date: 2009-10-20

Last Posted Date: 2015-04-10

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 34

Registration Number: NCT00998322

Locations: 🇺🇸
Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas, United States
🇺🇸
Montefiore Medical Center, New York, New York, United States

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

Phase 2

Completed

Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of the Lung

First Posted Date: 2009-10-20

Last Posted Date: 2016-03-31

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 32

Registration Number: NCT00998192

Locations: 🇺🇸
Ocala Oncology Center, Ocala, Florida, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Illinois Cancer Specialists, Niles, Illinois, United States

and more 14 locations

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma

First Posted Date: 2009-09-25

Last Posted Date: 2015-04-10

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 14

Registration Number: NCT00984464

Locations: 🇺🇸
Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas, United States

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation

Phase 2

Completed

Conditions: Carcinoma, Non-small Cell Lung

First Posted Date: 2009-03-13

Last Posted Date: 2015-12-02

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 37

Registration Number: NCT00861627

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
The Ohio State University Medical Center, James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy